{
  "docId": "019de073-9ed2-75f5-b4c4-69324b7a8310",
  "docSlug": "d4b095284b050177fedb9bcc804883cf",
  "documentTitle": "Albireo Pharma | Results Presentation Deck | 18 slides",
  "authorId": "albireo-pharma",
  "authorName": "Albireo Pharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 13,
  "pageCount": 18,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 14,
  "notes": "The slide highlights safety data for Odevixibat (Bylvay) over 24 weeks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9ed2-75f5-b4c4-69324b7a8310/13",
  "deckHref": "/decks/019de073-9ed2-75f5-b4c4-69324b7a8310",
  "deckJsonHref": "/decks/019de073-9ed2-75f5-b4c4-69324b7a8310.json",
  "deckAnchorHref": "/decks/019de073-9ed2-75f5-b4c4-69324b7a8310#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 1,
        "x": 0,
        "y": 0.83
      },
      "kind": "callout",
      "text": "Bylvay was well tolerated over 24 weeks, no discontinuations",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96bebd7b-106f-49e5-b048-a6e3226b9bc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "*≥5% in odevixibat group",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9d6fa30-78bc-418d-91e9-49ece852c7d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.74,
        "x": 0.13,
        "y": 0.165
      },
      "kind": "table",
      "text": "Safety data table comparing Placebo (N=17) and Odevixibat (N=35) across various adverse event categories.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc65171b-2584-46c8-96cb-b15853826a63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Well Tolerated with a Low Incidence of Diarrhea",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49699618-1b15-4517-826a-3a79e71af2e2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "0c03c65d-53cc-4b5e-ae37-c5d8792f2e98",
      "evidence": "Safety data table comparing Placebo (N=17) and Odevixibat (N=35) across various adverse event categories.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "706e309a-1edf-406d-a385-6a9dfcf6cec7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-14 present Bylvay as a solution, highlighting its efficacy and safety profile",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}